Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia , a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse.
http://www.medilexicon.com/medicalnews.php?newsid=253808
http://www.medilexicon.com/medicalnews.php?newsid=253808
No comments:
Post a Comment